| | DECEMBER 2021 19restrict. The method deploys specific inhibitors to shrink the NADH and ATP that are the principal energy source of the cancer cells, consequently weakening and killing the cells. The CEO goes on to mention how they could leverage two commonly used drugs called NYH817G and NYH100P, rearranging the constituents and developing the required anticancer therapy. This combination not only suggests higher efficacy but allows the therapy to be considerably inexpensive. "We are bringing to table a first-in-class anticancer drug based on ATP shrink that inhibits energy formation within the cancer cells and thereby defeats the disease," mentions Dr. Kim Hong-Yeoul, CEO of HaimBio.An important aspect, instrumental to HaimBio's efforts in the oncology space, is the attempt to eliminate the anticancer resistance that several patients develop over specific drugs. This is an incredible offering that HaimBio can bring in the medical arena to save lives. In addition to this, the CEO reflects upon the benefits of NYH817G that helps inhibit the functions of LDH from preventing the formation of lactic acid, which is an important energy source for tumour cells. Through these efforts, HaimBio has traversed a long journey with its innovative anticancer treatment, setting foot into the first metabolic anticancer drug trial in Korea. Moving ahead, IND-approved Starvanip® is expected to complete its first trial and enter into the next one around mid-2022. In fact, HaimBio has laid out plans to conduct its second phase of trials for rare cancers, including GBM, pancreatic cancer, and gradually cover other cancers such as breast cancer, NSCLC, and ovary cancer. The array of benefits that HaimBio aims to offer holistically addresses the needs in the oncology space and bridles the fatal impact of cancer. Their solutions are attempting to showcase not just a compelling and unique method of killing cancer cells but also look into the affordability and easy administering of the therapy, effectively raising hope among people to defeat this deadly disease. Dr. Kim Hong-Yeoul
< Page 9 | Page 11 >